Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TATUM-T vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
TATUM-T is a combination of ethynodiol diacetate, a progestin, and ethinyl estradiol, an estrogen. It suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation. Additionally, it increases viscosity of cervical mucus, impeding sperm penetration, and alters the endometrium to reduce implantation likelihood.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy,Treatment of moderate acne vulgaris in females at least 15 years old who have achieved menarche, are seeking contraception, and have failed topical therapy
Prevention of pregnancy (FDA-approved)
One tablet (ethinyl estradiol 0.035 mg / norgestimate 0.250 mg) orally once daily for 21 days, followed by 7 days of placebo.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Terminal elimination half-life of 12-15 hours in healthy adults; prolonged in renal impairment (up to 30 hours in creatinine clearance <30 m L/min) requiring dose adjustment
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Ethynodiol diacetate is rapidly deacetylated to ethynodiol and then extensively metabolized via reduction, hydroxylation, and conjugation; primary enzyme is CYP3A4. Ethinyl estradiol is metabolized primarily by CYP3A4 and undergoes phase II conjugation (glucuronidation and sulfation).
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Primarily renal (65-70% as unchanged drug); biliary/fecal (20-25%); minor metabolism to inactive glucuronide conjugates (<10%)
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
92-95% bound to albumin and alpha-1-acid glycoprotein
~99% bound to serum albumin and sex hormone-binding globulin.
0.3-0.5 L/kg (indicating moderate tissue distribution; primarily in extracellular fluid)
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: 90% (high first-pass metabolism negligible); Sublingual: 95%; Intravenous: 100%
Oral: ~70% due to first-pass metabolism.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min) or ESRD; use is not recommended.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in Child-Pugh class C (severe hepatic impairment) and in women with active liver disease. For Child-Pugh A or B, use is not recommended due to impaired hormone metabolism. If used, monitor liver function closely.
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not indicated for use before menarche. For post-menarche adolescents, use the same standard adult dosing regimen. Safety and efficacy established in females aged 16-35 years.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for use after menopause. No geriatric-specific dose adjustment is available.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age and with smoking (especially in women over 35 years of age). Women who use combined hormonal contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Thrombotic disorders: Venous thromboembolism, arterial thromboembolism (e.g., stroke, myocardial infarction); discontinue if symptoms occur.,Hepatic disease: Discontinue if jaundice develops; use with caution in patients with impaired liver function.,Risk of liver tumors (benign and malignant); discontinue if right upper quadrant pain or signs of intra-abdominal bleeding.,Elevated blood pressure: Monitor and discontinue if hypertension occurs.,Carbohydrate metabolism: May decrease glucose tolerance; monitor diabetic patients.,Hyperkalemia: Risk in patients with renal impairment or concomitant potassium-sparing diuretics due to drospirenone component; TATUM-T does not contain drospirenone, so minimal risk.,Gallbladder disease: May worsen existing disease.,Hereditary angioedema: May exacerbate.,Chloasma: May occur, avoid sun exposure.,Retinal thrombosis: Discontinue if unexplained partial or complete vision loss.
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Thrombophlebitis or thromboembolic disorders,History of deep vein thrombosis or pulmonary embolism,Cerebrovascular or coronary artery disease,Known or suspected breast cancer,Estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Pregnancy or suspected pregnancy,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Heavy smoking (≥15 cigarettes per day) in women over 35 years of age
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
No specific food interactions. Avoid excessive copper supplements as the IUD releases copper locally; systemic absorption is minimal but caution in Wilson's disease.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
TATUM-T contains cupric sulfate and zinc acetate. Copper is a required trace element but excess can be teratogenic. In animal studies, high doses of copper caused fetal malformations and embryotoxicity. In human pregnancy, therapeutic use of copper is generally not associated with major teratogenic risk when used within recommended doses. However, data are limited. For the first trimester, there is a theoretical risk of copper toxicity affecting organogenesis; for second and third trimesters, risks include potential for copper accumulation and fetal hepatic toxicity. Zinc is essential but high doses may interfere with copper absorption. Overall, use only if clearly needed.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Copper is excreted into breast milk in small amounts and is a normal component of human milk. Zinc is also excreted. The M/P ratio for copper is approximately 0.1-0.3 and for zinc is about 0.5-1.0. At therapeutic doses, TATUM-T is unlikely to cause adverse effects in a breastfed infant. However, caution is advised due to potential for copper or zinc accumulation if maternal doses are high. Consider monitoring infant copper/zinc levels if prolonged use.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
No established dosage adjustments are recommended for TATUM-T during pregnancy. However, pregnancy may alter copper metabolism with increased ceruloplasmin, potentially leading to lower free copper levels. Monitor serum copper levels to ensure therapeutic efficacy and avoid deficiency. If copper levels drop, consider increasing dose under medical supervision. Zinc dosing may remain unchanged.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
TATUM-T is a copper-containing intrauterine device (IUD) for long-term contraception (up to 10 years). It can be used for emergency contraception if inserted within 5 days of unprotected intercourse. Mechanism involves copper-induced sperm toxicity and inhibition of implantation. May be used in nulliparous women. Counsel patients about expected bleeding pattern changes: increased menstrual flow and spotting initially. Monitor for IUD expulsion or perforation, especially postpartum. Do not use in Wilson's disease or copper allergy.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
TATUM-T provides effective contraception for up to 10 years but does not protect against STDs; use condoms for protection.,You may experience heavier periods and spotting, especially in the first 3-6 months after insertion.,Check for the IUD strings after each menstrual period to ensure it is in place.,If you miss a period or have symptoms of pregnancy, contact your healthcare provider immediately.,Insertion may cause cramps and discomfort that typically resolve within a few hours to days.,Seek medical attention if you have severe pelvic pain, foul-smelling discharge, or fever, which could indicate infection.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TATUM-T vs AFIRMELLE, answered by our medical review team.
TATUM-T is a Oral Contraceptive that works by TATUM-T is a combination of ethynodiol diacetate, a progestin, and ethinyl estradiol, an estrogen. It suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation. Additionally, it increases viscosity of cervical mucus, impeding sperm penetration, and alters the endometrium to reduce implantation likelihood.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TATUM-T and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TATUM-T is: One tablet (ethinyl estradiol 0.035 mg / norgestimate 0.250 mg) orally once daily for 21 days, followed by 7 days of placebo.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TATUM-T and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TATUM-T is classified as Category C. TATUM-T contains cupric sulfate and zinc acetate. Copper is a required trace element but excess can be teratogenic. In animal studies, high doses of copper caused fetal malformatio. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.